
## Gert Van Zyl

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10696448/publications.pdf Version: 2024-02-01



CEDT VAN 7VI

#	Article	IF	CITATIONS
1	Detection of a SARS-CoV-2 variant of concern in South Africa. Nature, 2021, 592, 438-443.	27.8	1,381
2	Sixteen novel lineages of SARS-CoV-2 in South Africa. Nature Medicine, 2021, 27, 440-446.	30.7	326
3	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science, 2021, 374, 423-431.	12.6	144
4	A genomics network established to respond rapidly to public health threats in South Africa. Lancet Microbe, The, 2020, 1, e229-e230.	7.3	46
5	Future technologies for monitoring HIV drug resistance and cure. Current Opinion in HIV and AIDS, 2017, 12, 182-189.	3.8	45
6	HIV Drug Resistance (HIVDR) in Antiretroviral Therapy-NaÃ⁻ve Patients in Tanzania Not Eligible for WHO Threshold HIVDR Survey Is Dramatically High. PLoS ONE, 2011, 6, e23091.	2.5	43
7	Assessment of HIV transfusion transmission risk in South Africa: a 10â€year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes. Transfusion, 2019, 59, 267-276.	1.6	40
8	Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS ONE, 2016, 11, e0166305.	2.5	40
9	Lessons in diagnostic virology: expected and unexpected sources of error. Reviews in Medical Virology, 2019, 29, e2052.	8.3	23
10	Multiple Early Introductions of SARS-CoV-2 to Cape Town, South Africa. Viruses, 2021, 13, 526.	3.3	20
11	Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS Research and Human Retroviruses, 2022, 38, 455-462.	1.1	13
12	Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥500 Cells/ÂμL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa. Clinical Infectious Diseases, 2020, 70, 395-403.	5.8	12
13	HIV incidence in South African blood donors from 2012 to 2016: a comparison of estimation methods. Vox Sanguinis, 2021, 116, 71-80.	1.5	12
14	Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy, 2022, 77, 483-491.	3.0	8
15	High positive HIV serology results can still be false positive. IDCases, 2020, 21, e00849.	0.9	6
16	An assessment of hepatitis B virus prevalence in South African young blood donors born after the implementation of the infant hepatitis B virus immunization program: Implications for transfusion safety. Transfusion, 2021, 61, 2688-2700.	1.6	5
17	Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C. PLoS Computational Biology, 2021, 17, e1008363.	3.2	2
18	PhyloPi: An affordable, purpose built phylogenetic pipeline for the HIV drug resistance testing facility. PLoS ONE, 2019, 14, e0213241.	2.5	1